Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Bata India Ltd, Biocon Ltd, Go Digit General Insurance Ltd, Max Financial Services Ltd are among the other stocks to see a surge in volumes on BSE today, 14 January 2026.
Polycab India Ltd clocked volume of 8.35 lakh shares by 10:46 IST on BSE, a 63.27 times surge over two-week average daily volume of 13203 shares. The stock lost 2.28% to Rs.7,397.00. Volumes stood at 21247 shares in the last session.
Bata India Ltd registered volume of 53946 shares by 10:46 IST on BSE, a 9.18 fold spurt over two-week average daily volume of 5878 shares. The stock slipped 0.28% to Rs.905.40. Volumes stood at 5542 shares in the last session.
Biocon Ltd registered volume of 5.65 lakh shares by 10:46 IST on BSE, a 6.36 fold spurt over two-week average daily volume of 88828 shares. The stock rose 1.03% to Rs.381.20. Volumes stood at 2.12 lakh shares in the last session.
Go Digit General Insurance Ltd saw volume of 23620 shares by 10:46 IST on BSE, a 5.03 fold spurt over two-week average daily volume of 4699 shares. The stock dropped 4.29% to Rs.324.40. Volumes stood at 5848 shares in the last session.
Max Financial Services Ltd notched up volume of 1.02 lakh shares by 10:46 IST on BSE, a 4.4 fold spurt over two-week average daily volume of 23060 shares. The stock slipped 0.26% to Rs.1,642.10. Volumes stood at 95781 shares in the last session.
Shares of Steel Authority of India (SAIL) and Sammaan Capital are banned from F&O trading on 7 January 2026.
Stocks to Watch:
Biocon’s subsidiary, Biocon Biologics will introduce three new oncology biosimilars at a US event.
Titan Company’s consumer business registered a growth of 40% YoY in Q3FY26. A total of 56 stores (net) were added during the quarter expanding Titan’s combined retail network presence to 3,433 stores.
Lodha Developers’ pre sales jumped 25% to Rs 56,200 crore in Q3 FY26 compared with Rs 45,100 crore in Q3 FY25. Collections declined 17% YoY to Rs 35,600 crore in Q3 FY26.
Jubilant Foodworks’ consolidated revenue stood at Rs 2,438.7 crore in Q3 FY26, up 13.4% YoY. Domino’s recorded a Like-For-Like (LFL) growth of 5%.
Senco Gold reported a 51% revenue growth in Q3 FY26, driven by robust performances across its businesses. The retail business reported around 49% growth while SSSG growth stood at 39%.
Godrej Consumer Products said that its standalone business is well positioned to deliver double-digit revenue growth for the quarter, underpinned by close to double-digit underlying volume growth (UVG), albeit on a supportive comparator. Personal Care is expected to record mid-single-digit value growth, driven by a marked recovery in the soaps category.
Biocon Biologics and subsidiary of Biocon will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.
The company is set to unveil three new biosimilar oncology assets—Trastuzumab/Hyaluronidase (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®), and Pembrolizumab (Keytruda®)—at the 2026 J.P. Morgan Healthcare Conference. With these new oncology assets, including two PD-1 inhibitors, Biocon Biologics will have one of the most comprehensive oncology portfolios in the industry. This will enable the company to broaden the availability of critical oncology therapies through cost‑effective biosimilar alternatives. Global sales of Keytruda were $29.5 billion in 2024; Opdivo sales in 2024 were $9.3 billion; and Herceptin SC and Herceptin HYLECTA combined sales were $1.72 billion in 2024. These new assets are among the largest oncology biologics scheduled to lose exclusivity over the next five years and will join Biocon Biologics' existing portfolio of 17 oncology medications, which includes Pertuzumab (Perjeta®) that was recently submitted to the FDA, as well as several small molecule cancer therapies. The company's oncology portfolio, including undisclosed products, represents an over $75 billion opportunity, or approximately 35% of the global oncology pharmaceutical market.
Biocon recently announced its plans to integrate Biocon Biologics as a wholly owned subsidiary. This integration marks a pivotal step in combining the businesses to leverage the global commercial infrastructure, simplifying the corporate structure and strengthening Biocon's global position to lead in diabetes, oncology, and immunology — therapeutic areas that together account for nearly 40% of global pharmaceutical revenues. The integration, which is expected to be completed no later than March 31, 2026, will also uniquely position Biocon as the only company offering both biosimilar insulins and generics for complex peptides, including GLP-1s, to address the full spectrum of diabetes care. The integration will enhance Biocon Biologics' ability to deliver innovative, affordable medicines to over 6 million patients in more than 120 markets worldwide. Post integration and upon requisite approvals, Shreehas Tambe will take on the role of CEO & Managing Director of the combined business.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics said: “At the 2026 J.P. Morgan Healthcare Conference, we will share how our integration with Biocon Limited strengthens Biocon Biologics' ability to deliver both biosimilars and generics at global scale. This will position us to better serve patients across diabetes, oncology, and immunology, including expanding access to biosimilar insulins and generic GLP-1 peptides amid the rising diabetes and obesity burden. Guided by a science-led, R&D approach, we are advancing a strong pipeline with 17 oncology assets to meet varied patient needs. These efforts underscore our commitment to providing affordable, high-quality medicines for patients around the world.”
Under the terms of this agreement, FKB will participate in the development of the product and will offset certain development costs incurred by Biocon Biologics. In turn, Biocon Biologics will pay a technology license fee and royalties on sales to FKB for a specified tenure.
Commercial production of the biosimilar Adalimumab at Biocon Biologics’ facilities will commence after successful completion of technology transfer and receipt of necessary regulatory approvals.
Biocon Biologics initially acquired the commercial rights to biosimilar Adalimumab in 2022 through its acquisition of Viatris’ global biosimilars business. Viatris had previously in-licensed the product from FKB. Under the earlier arrangement, FKB manufactures and supplies the product to Biocon Biologics, which holds global commercial rights for HULIO.
Adalimumab is one of the three immunology biosimilars in Biocon Biologics’ overall portfolio, which underscores the company’s strategic focus on expanding access to biologics for immune-mediated diseases worldwide.
Shreehas Tambe, CEO & Managing Director, Biocon Biologics, said, “This agreement with FKB provides Biocon Biologics the manufacturing rights to biosimilar Adalimumab, granting us end-to-end control over the product. This strategic move enhances flexibility and cost efficiency, reinforcing our commitment to expanding affordable access to high-quality biologics for patients with inflammatory diseases globally.”
Biocon is a global biopharma company dedicated to improving affordable access to therapies for chronic conditions such as diabetes, cancer, and autoimmune diseases.
On a consolidated basis, Biocon reported a net profit of Rs 84.50 crore in Q2 September 2025 as against a net loss of Rs 16 crore in Q2 September 2024. Net sales rose 20.24% YoY to Rs 4262.50 crore in Q2 September 2025.
The counter added 0.43% to currently trade at Rs 400.75 on the BSE.
Biocon Ltd is up for a fifth straight session in a row. The stock is quoting at Rs 399.7, up 0.1% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.01% on the day, quoting at 26175.65. The Sensex is at 85535.57, down 0.04%. Biocon Ltd has risen around 1.13% in last one month.
Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has risen around 1.82% in last one month and is currently quoting at 22927.9, down 0.11% on the day. The volume in the stock stood at 12.75 lakh shares today, compared to the daily average of 34.28 lakh shares in last one month.
The benchmark December futures contract for the stock is quoting at Rs 400.5, up 0.18% on the day. Biocon Ltd is up 16.02% in last one year as compared to a 10.32% spurt in NIFTY and a 1.52% spurt in the Nifty Pharma index.
The PE of the stock is 0 based on TTM earnings ending September 25.
Securities in F&O Ban:
Sammaan Capital shares are banned from F&O trading on 19 December 2025.
IPO Listing
ICICI Prudential Asset Management Company's shares will list on the stock exchanges today. The issue price was set at Rs 2,165 per share. The issue was subscribed 39.17 times. It opened for bidding on 12 December 2025 and it closed on 16 December 2025. The price band was Rs 2,061-2,165.
Reliance Industries announced that its arm, Reliance Consumer, has acquired a majority stake in Udhaiyam Agro Foods.
Lupin announced that its subsidiaries in the Philippines (Multicare Pharmaceuticals) and Brazil (MedQuímica) have signed an agreement with Neopharmed Gentili to market the brand Plasil in Brazil and the Philippines.
Tata Consultancy Services announced that its subsidiary, TCS Iberoamerica S.A., has incorporated a technology company, Sociedad Anónima, in Costa Rica.
HCL Technologies announced that it has signed a definitive agreement to acquire the telecom solutions business of Hewlett Packard Enterprise for USD 160 million.
Narayana Hrudayalaya announced that its board will meet shareholders and creditors on January 19 to seek approval for the merger scheme of Meridian Medical Research into the company.
Hexaware Technologies announced that its Board has approved the merger of Softcrylic Tech Solutions and Mobiquity SoftTech with the company.
Mishra Dhatu Nigam announced that it has secured orders worth Rs 121.75 crore. Its open order position as of date stands at approximately Rs 2,520 crore.
Aeroflex Industries announced that its board has approved a capacity addition of 13,000 units per year for liquid cooling skids used in data centres. The plan includes installing robotic and automated welding lines for flexible stainless-steel hose assemblies and setting up an annealing plant for stainless-steel braided hoses for mission-critical applications, as per management requirements.
Bharti Hexacom announced the appointment of Kathikeyan Velu as Chief Financial Officer, effective January 1, 2026. Akhil Garg has resigned as CFO due to organizational movement within the Bharti Group.
Rossari Biotech announced that it has incorporated wholly owned subsidiary Rossari (Singapore) on 18 December 2025.
Biocon announced that its New Jersey unit has received an Establishment Inspection Report (EIR) from the US FDA with a Voluntary Action Indicated (VAI) status.
Biocon announced the launch of its GLP-1 peptide, Liraglutide, for diabetes (gVictoza®) and obesity (gSaxenda®), in the Netherlands through its distribution partner Pharmamedic B.V. The drug-device combination will be marketed in the Netherlands under the brand names Diavorin® for diabetes and Vobexoryn® for chronic weight management.
The launch follows the approval from the Medicines Evaluation Board (MEB), Netherlands, earlier this year and will mark the first country in the European Union where the Company will directly launch Liraglutide under its own brand.
The drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management.
Siddharth Mittal, chief executive officer and managing director, Biocon, said: “The launch of Liraglutide in the Netherlands marks a significant milestone in expanding Biocon’s GLP-1 portfolio across key global markets, and reinforces the strategic importance of peptide-based therapies within our portfolio.
With our vertically integrated, end-to-end capabilities, we are uniquely positioned to deliver high-quality, affordable metabolic treatments at scale. Launching Diavorin and Vobexoryn under our own brand in Europe reflects not only our scientific and manufacturing excellence, but also our long-standing commitment to broadening access to advanced therapies for diabetes and obesity.'
On a consolidated basis, Biocon reported net profit of Rs 84.50 crore in Q2 September 2025 as against net loss of Rs 16 crore in Q2 September 2024. Net sales rose 20.24% YoY to Rs 4262.50 crore in Q2 September 2025.
The scrip shed 0.21% to currently trade at Rs 385.85 on the BSE.
The agreement clears the way for Biocon Biologics to commercialize Yesafili globally. Yesafili is a vascular endothelial growth factor (VEGF) inhibitor used to treat multiple ophthalmology conditions, including neovascular (wet AMD) age-related macular degeneration, visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), diabetic macular oedema (DME), and myopic choroidal neovascularisation (myopic CNV).
As part of the agreement, all pending litigation among Biocon Biologics, Regeneron, and Bayer has been dismissed. Biocon Biologics plans to launch Yesafili in the United Kingdom in January 2026, followed by launches in other settled countries in March 2026, or earlier in certain circumstances. The other terms of the settlement remain confidential.
The European Commission (EC) and the Medicines & Healthcare products Regulatory Agency (MHRA) have previously approved YESAFILI.
Yesafili has already received approval from the European Commission (EC) and the UK Medicines & Healthcare products Regulatory Agency (MHRA). Biocon Biologics had earlier secured market entry for the U.S. in April 2025, targeting the second half of calendar year 2026, and launched the product in Canada earlier this year, with market entry secured in March 2024.
Shreehas Tambe, CEO & managing director, Biocon Biologics, said, “This settlement paves the way for Biocon Biologics to make available our biosimilar Aflibercept globally. This milestone expands our presence in the ophthalmology therapeutic area as we work closely with healthcare systems to increase access to patients everywhere.”
The counter added 1.34% to currently trade at Rs 386.65 on the BSE.